Splenectomy in Patients with Agnogenic Myeloid Metaplasia: an Analysis of 321 Published Cases

J, Benbassat; Penchas, S; Ligumski, M.

doi:10.1111/j.1365-2141.1979.tb01125.x

Cited by 50 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, Mulder et al [3] re ported a median postoperative survival of 4.2 years in 19 patients with AMM who had splenectomy shortly after diagnosis. Similar ly, in a recent review of published cases of splenectomy in AMM, we showed that the postoperative mortality was significantly higher in patients operated at advanced stages of the disease, as judged by the plate let level and splenic weight [4].…”

Section: Introductionsupporting

confidence: 50%

‘Early’ Splenectomy and Survival in Agnogenic Myeloid Metaplasia

J¹,

Penchas²

1981

Acta Haematol

Self Cite

View full text Add to dashboard Cite

The data available for 338 cases of splenectomy in agnogenic myeloid metaplasia published since 1940 were retrieved from the literature and analyzed. The median survival of cases operated upon at an early stage of the disease (as judged by their hemoglobin level, platelet number, and splenic size) was compared with the survival reported in conservatively treated patients diagnosed at an early stage of agnogenic myeloid metaplasia. Survival time since diagnosis of patients with early splenectomy was similar to, or shorter than, that reported in conservatively treated patients with early agnogenic myeloid metaplasia.

show abstract

Section: Introductionsupporting

confidence: 50%

‘Early’ Splenectomy and Survival in Agnogenic Myeloid Metaplasia

J¹,

Penchas²

1981

Acta Haematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, this decision should be carefully made, given the substantial risk associated with the procedure. Thus, in a retrospective analysis of 15 series in the literature, including a total of 321 splenectomized patients, the operative mortality was 13AE4%, early morbidity 45AE3% and late morbidity 16AE3% (Benbassat et al, 1979). In two series from single institutions (Barosi et al, 1993b;Tefferi et al, 2000), operative morbidity was 39AE3% and 31%, and mortality 8AE4% and 9%, respectively, with the latter increasing to 26% when the 3-month postsplenectomy period was considered .…”

Section: Splenectomymentioning

confidence: 99%

Modern management of myelofibrosis

Cervantes

2005

Br J Haematol

View full text Add to dashboard Cite

SummaryThe conventional treatment of myelofibrosis involves a wait‐and‐see approach for asymptomatic patients, oral chemotherapy for the hyperproliferative forms of the disease, androgens or erythropoietin for the anaemia, and splenectomy in selected patients. Low‐dose thalidomide plus prednisone is a well‐tolerated therapy for the anaemia and the thrombocytopenia of myelofibrosis, whereas imatinib has shown little efficacy. Allogeneic stem cell transplantation (allo‐SCT) is the only curative therapy for myelofibrosis. Its standard modality has an associated mortality of about 30% and can be applied to younger patients with high‐risk disease or resistant to conventional treatment. Reduced‐intensity conditioning allo‐SCT involves a low mortality and is a promising therapy for patients aged 45–70 years old with the above characteristics. Autologous SCT is a palliative therapy for patients resistant to conventional treatment who lack a suitable donor. The next candidates for the treatment of myelofibrosis are the thalidomide derivatives, the proteasome inhibitors, and vascular endothelial growth factor neutralizing antibodies.

show abstract

“…When available, clinical, laboratory and follow-up data were compiled for each individual case according to a predesignated format, and a digital computer was used for the analysis of the data. Breakdown of postoperative survival by date of publication showed that postoperative survival has not changed significantly during the last four decades (Benbassat et al, 1979).…”

Section: Methodsmentioning

confidence: 99%

“…The authors have recently surveyed the literature on splenectomy in AMM and reported a preliminary analysis of the prognostic significance of several clinical and laboratory variables at splenectomy (Benbassat et al, 1979). In this paper a further evaluation is presented of the patients' age, haemoglobin level, platelet count, splenic size, serum alkaline phosphatase and combinations thereof as predictors of postoperative survival.…”

Section: Introductionmentioning

confidence: 99%

Splenectomy in agnogenic myeloid metaplasia: factors of possible prognostic significance

Penchas

Sukenik²,

Steinwel

et al. 1982

Postgraduate Medical Journal

Self Cite

View full text Add to dashboard Cite

SummaryThe available data of 338 cases of splenectomy in agnogenic myeloid metaplasia published since 1940 were retrieved from the literature and analysed. Postoperative survival was significantly shorter in patients with anaemia, massive splenomegaly or elevated serum alkaline phosphatase. Younger age or normal platelet counts were associated with a longer postoperative survival than that in older patients and in patients with low platelet counts respectively. The shortest median postoperative survival was found in: patients in whom serum alkaline phosphatase exceeded twice the upper limit of the normal; patients with anaemia (less than 10 g/dl haemoglobin) and massive splenomegaly (above 3 kg); and patients with anaemia and a splenic weight less than one kg.

show abstract

Splenectomy in Patients with Agnogenic Myeloid Metaplasia: an Analysis of 321 Published Cases

Cited by 50 publications

References 20 publications

‘Early’ Splenectomy and Survival in Agnogenic Myeloid Metaplasia

‘Early’ Splenectomy and Survival in Agnogenic Myeloid Metaplasia

Modern management of myelofibrosis

Splenectomy in agnogenic myeloid metaplasia: factors of possible prognostic significance

Contact Info

Product

Resources

About